With the introduction of today’s standard of care in earlier lines of therapy using different combinations of PIs, IMiDs, and anti-CD38 Abs, the prognosis for a large proportion of MM patients has improved significantly, both in newly diagnosed MM patients and also in the relapsed/refractory setting. The gene discussed is CD38; the disease is Miyoshi myopathy.